Application of Minimal Clinically Important Difference in Outcome Assessment Tools for Bronchiectasis Treatment

doi:10.12114/j.issn.1007-9572.2022.0290

Chinese General Practice ›› 2022, Vol. 25 ›› Issue (30): 3739-3746.DOI: 10.12114/j.issn.1007-9572.2022.0290

Special Issue: 患者报告结局最新文章合辑

• Clinical Hot Topic • Previous Articles Next Articles

Application of Minimal Clinically Important Difference in Outcome Assessment Tools for Bronchiectasis Treatment

1. Henan University of Chinese Medicine, Zhengzhou 450046, China
2. Department of Respiratory Medicine, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China

Received:2022-04-10 Revised:2022-06-12 Published:2022-10-20 Online:2022-06-30
Contact: Yang XIE
About author:
GUAN J R, REN J M, XIE Y, et al. Application of minimal clinically important difference in outcome assessment tools for bronchiectasis treatment[J]. Chinese General Practice, 2022, 25 (30) : 3739-3746, 3754.

最小临床重要差值在支气管扩张症疗效测评工具中的应用与思考

1．450046　河南省郑州市，河南中医药大学
2．450000　河南省郑州市，河南中医药大学第一附属医院呼吸科

通讯作者: 谢洋
作者简介:
关佳瑞，任嘉铭，谢洋，等.最小临床重要差值在支气管扩张症疗效测评工具中的应用与思考[J].中国全科医学，2022，25（30）：3739-3746，3754.[www.chinagp.net] 作者贡献：关佳瑞进行文章的构思与设计，撰写论文并对文章负责；关佳瑞、张彭负责文章的资料收集与整理；任嘉铭负责文章的修订；谢洋负责文章的质量控制及审校，对文章整体负责、监督管理。
基金资助:
国家自然科学基金重点项目(81830116); 国家重点研发计划(2018YFC1704806); 河南省自然科学基金优秀青年科学基金项目(212300410056); 河南省科技攻关计划(172102310200); 河南省第二批中医药拔尖人才项目(豫卫中医函〔2021〕15号)

Abstract

Abstract:

Increased bronchiectasis (BE) prevalence has imposed heavy economic burden on patients and their families, greatly affecting the quality of life of patients. With increased use of patient reported outcome (PRO) in bronchiectasis treatment assessment, researchers not only focus on statistical pre-and post-treatment differences (P<0.05) , but also pay attention to minimal clinically important difference (MCID) . Currently, there is still a lack of relevant data about MCID in BE-PRO assessment tools. We reviewed the latest research on the use of MCID in BE-PRO assessment tools, aiming at providing a quantitative basis for outcome assessment in BE treatment.

Key words: Bronchiectasis, Patient reported outcome, Quality of life, Minimal clinically important difference, Measurement instrument, Scale

摘要：

支气管扩张症（BE）发病率逐年增高，给患者及家庭造成了沉重的经济负担，对患者生存质量影响较大。随着患者报告结局（PRO）在BE临床应用中的增多，研究者不再只关注其统计学差异（P<0.05），其最小临床重要差值（MCID）也逐渐成为研究热点。当前对BE-PRO测评工具的MCID研究还缺乏相关数据，本文概述了MCID在BE-PRO测评工具中的研究现状，以期为BE相关临床疗效评价提供量化标准及参考依据。

关键词: 支气管扩张症, 患者报告结局, 生活质量, 最小临床重要差值, 测评工具, 量表

Jiarui GUAN,Jiaming REN,Yang XIE, et al. Application of Minimal Clinically Important Difference in Outcome Assessment Tools for Bronchiectasis Treatment[J]. Chinese General Practice, 2022, 25(30): 3739-3746. DOI: 10.12114/j.issn.1007-9572.2022.0290.
关佳瑞,任嘉铭,谢洋等. 最小临床重要差值在支气管扩张症疗效测评工具中的应用与思考[J]. 中国全科医学, 2022, 25(30): 3739-3746. DOI: 10.12114/j.issn.1007-9572.2022.0290.

Figures/Tables 1

References 71

[1]	何权瀛.成人支气管扩张症诊治专家共识[J]. 中华结核和呼吸杂志，2012(7):485-492. DOI：10.3760/cma.j.issn.1001-0939.2012.07.003.
[2]	GOEMINNE P C, HERNANDEZ F, DIEL R，et al. The economic burden of bronchiectasis-known and unknown：a systematic review[J]. BMC Pulm Med，2019，19(1):54. DOI：10.1186/s12890-019-0818-6.
[3]	SALAS APAZA J A, FRANCO J V A, MEZA N，et al. Minimal clinically important difference：the basics[J]. Medwave，2021，21(3):e8149. DOI：10.5867/medwave.2021.03.8149.
[4]	JAESCHKE R, SINGER J, GUYATT G H. Measurement of health status. Ascertaining the minimal clinically important difference[J]. Control Clin Trials，1989，10(4):407-415. DOI：10.1016/0197-2456(89)90005-6.
[5]	SCHÜNEMANN H J, GUYATT G H. Commentary--goodbye M（C）ID! Hello MID，where do you come from? [J]. Health Serv Res，2005，40(2):593-597. DOI：10.1111/j.1475-6773.2005.00374.x.
[6]	NORMAN G R, SLOAN J A, WYRWICH K W. Interpretation of changes in health-related quality of life：the remarkable universality of half a standard deviation[J]. Med Care，2003，41(5):582-592. DOI：10.1097/01.MLR.0000062554.74615.4C.
[7]	REVICKI D, HAYS R D, CELLA D，et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes[J]. J Clin Epidemiol，2008，61(2):102-109. DOI：10.1016/j.jclinepi.2007.03.012.
[8]	BROZEK J L, GUYATT G H, SCHÜNEMANN H J. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure[J]. Health Qual Life Outcomes，2006，4:69. DOI：10.1186/1477-7525-4-69.
[9]	REVICKI D A, CELLA D, HAYS R D，et al. Responsiveness and minimal important differences for patient reported outcomes[J]. Health Qual Life Outcomes，2006，4:70. DOI：10.1186/1477-7525-4-70.
[10]	BARRETT B, BROWN R, MUNDT M. Comparison of anchor-based and distributional approaches in estimating important difference in common cold[J]. Qual Life Res，2008，17(1):75-85. DOI：10.1007/s11136-007-9277-2.
[11]	薛红红，杨铮，万崇华，等. 基于量表得分的最小临床重要性差值（MCID）制定方法[J]. 中国卫生统计，2019，36(3):436-440.
[12]	路桃影，吴大嵘. 最小重要差值及其在中医临床研究中的应用展望[J]. 中国中西医结合杂志，2013，33(4):544-548,558.
[13]	SNYDER C F, JENSEN R E, SEGAL J B，et al. Patient-reported outcomes（PROs）：putting the patient perspective in patient-centered outcomes research[J]. Med Care，2013，51(8 Suppl 3):S73-79. DOI：10.1097/MLR.0b013e31829b1d84.
[14]	WARE J E Jr, SHERBOURNE C D. The MOS 36-item short-form health survey（SF-36）. I. Conceptual framework and item selection[J]. Med Care，1992，30(6):473-483.
[15]	SWIGRIS J J, BROWN K K, BEHR J，et al. The SF-36 and SGRQ：validity and first look at minimum important differences in IPF[J]. Respir Med，2010，104(2):296-304. DOI：10.1016/j.rmed.2009.09.006.
[16]	ZIGMOND A S, SNAITH R P. The hospital anxiety and depression scale[J]. Acta Psychiatr Scand，1983，67(6):361-370. DOI：10.1111/j.1600-0447.1983.tb09716.x.
[17]	SMID D E, FRANSSEN F M, HOUBEN-WILKE S，et al. Responsiveness and MCID estimates for CAT，CCQ，and HADS in patients with COPD undergoing pulmonary rehabilitation：a prospective analysis[J]. J Am Med Dir Assoc，2017，18(1):53-58. DOI：10.1016/j.jamda.2016.08.002.
[18]	WYNNE S C, PATEL S, BARKER R E，et al. Anxiety and depression in bronchiectasis：response to pulmonary rehabilitation and minimal clinically important difference of the Hospital Anxiety and Depression Scale[J]. Chron Respir Dis，2020，17:1479973120933292. DOI：10.1177/1479973120933292.
[19]	CHAN S L, CHAN-YEUNG M M, OOI G C，et al. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis[J]. Chest，2002，122(6):2030-2037. DOI：10.1378/chest.122.6.2030.
[20]	蔡映云，李倬哲，方宗君. 慢性阻塞性肺疾病患者生存质量评估[J]. 中华全科医师杂志，2004，3(4):225-227. DOI：10.3760/cma.j.issn.1671-7368.2004.04.005.
[21]	祖菲亚·努尔买买提，黄霞，阿丽亚·哈力克，等. 肺康复运动用于支气管扩张急性加重患者恢复期的效果评价[J]. 临床肺科杂志，2022，27(1):50-53. DOI：10.3969/j.issn.1009-6663.2022.01.011.
[22]	李扬懿，孙美妹，魏呈祥，等. 肺康复对支气管扩张症患者肺功能及生活质量的影响[J]. 临床肺科杂志，2021，26(12):1847-1851. DOI：10.3969/j.issn.1009-6663.2021.12.014.
[23]	李静芬，田景炜，陈瑞，等. 圣乔治呼吸问卷对慢性阻塞性肺疾病患者生活质量的调查[J]. 现代生物医学进展，2016，16(36):7091-7094. DOI：10.13241/j.cnki.pmb.2016.36.023.
[24]	冯京帅，辛大永. 二甲消癥汤对气虚血瘀型特发性肺纤维化患者圣乔治呼吸问卷积分影响[J]. 北京中医药，2017，36(1):71-73. DOI：10.16025/j.1674-1307.2017.01.021.
[25]	张美荣，陆文春. 生存质量评估简表和圣乔治呼吸问卷评价煤工尘肺患者生存质量的研究[J]. 职业与健康，2015，31(22):3073-3076. DOI：10.13329/j.cnki.zyyjk.2015.1060.
[26]	JONES P W. St. George's Respiratory Questionnaire：MCID[J]. COPD，2005，2(1):75-79. DOI：10.1081/copd-200050513.
[27]	SWIGRIS J J, KUSCHNER W G, JACOBS S S，et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis：a systematic review[J]. Thorax，2005，60(7):588-594. DOI：10.1136/thx.2004.035220.
[28]	REHMAN A U, HASSALI M A A, HARUN S N，et al. Validation and clinical interpretation of the St George's respiratory questionnaire for COPD （SGRQ-C） after adaptation to Malaysian language and culture，in patients with COPD[J]. Health Qual Life Outcomes，2020，18(1):138. DOI：10.1186/s12955-020-01393-1.
[29]	侯年. 三种剂量的茚达特罗治疗中重度慢阻肺疗效及安全性的网状Meta分析[D]. 兰州：兰州大学，2019.
[30]	GUYATT G H, BERMAN L B, TOWNSEND M，et al. A measure of quality of life for clinical trials in chronic lung disease[J]. Thorax，1987，42(10):773-778. DOI：10.1136/thx.42.10.773.
[31]	VODANOVICH D A, BICKNELL T J, HOLLAND A E，et al. Validity and reliability of the chronic respiratory disease questionnaire in elderly individuals with mild to moderate non-cystic fibrosis bronchiectasis[J]. Respiration，2015，90(2):89-96. DOI：10.1159/000430992.
[32]	WYRWICH K W, TIERNEY W M, WOLINSKY F D. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life[J]. J Clin Epidemiol，1999，52(9):861-873. DOI：10.1016/s0895-4356(99)00071-2.
[33]	TU S P, MCDONELL M B, SPERTUS J A，et al. A new self-administered questionnaire to monitor health-related quality of life in patients with COPD. Ambulatory Care Quality Improvement Project （ACQUIP） Investigators[J]. Chest，1997，112(3):614-622. DOI：10.1378/chest.112.3.614.
[34]	贾秀芬，王君俏，杨雅，等. SOLQ对社区COPD病人生活质量评估的价值研究[J]. 护理研究，2015，29(29):3613-3616. DOI：10.3969/j.issn.1009-6493.2015.29.010.
[35]	许利萍，王丹丹，王进，等. 西雅图阻塞性肺疾病评分用于老年COPD患者优质护理效果相关因素分析[J]. 安徽医学，2016，37(3):350-352. DOI：10.3969/j.issn.1000-0399.2016.03.031.
[36]	BULCUN E, ARSLAN M, EKICI A，et al. Quality of life and bronchial hyper-responsiveness in subjects with bronchiectasis：validation of the Seattle obstructive lung disease questionnaire in bronchiectasis[J]. Respir Care，2015，60(11):1616-1623. DOI：10.4187/respcare.03906.
[37]	QUITTNER A L, MARCIEL K K, SALATHE M A，et al. A preliminary quality of life questionnaire-bronchiectasis：a patient-reported outcome measure for bronchiectasis[J]. Chest，2014，146(2):437-448. DOI：10.1378/chest.13-1891.
[38]	MAGGE A, ASHRAF S, QUITTNER A L，et al. Quality of life in patients with bronchiectasis：a 2-year longitudinal study[J]. Ann Transl Med，2019，7(14):334. DOI：10.21037/atm.2019.06.62.
[39]	QUITTNER A L, O´DONNELL A E, SALATHE M A，et al. Quality of Life Questionnaire-Bronchiectasis：final psychometric analyses and determination of minimal important difference scores[J]. Thorax，2015，70(1):12-20. DOI：10.1136/thoraxjnl-2014-205918.
[40]	OLVEIRA C, OLVEIRA G, ESPILDORA F，et al. Validation of a quality of life questionnaire for bronchiectasis：psychometric analyses of the Spanish QOL-B-V3.0[J]. Qual Life Res，2014，23(4):1279-1292. DOI：10.1007/s11136-013-0560-0.
[41]	QUELLHORST L, BARTEN-NEINER G, DE ROUX A，et al. Psychometric validation of the German translation of the quality of life questionnaire-bronchiectasis（QOL-B）-data from the German bronchiectasis registry PROGNOSIS[J]. J Clin Med，2022，11(2):441. DOI：10.3390/jcm11020441.
[42]	周慧姣，桑玉兰，霍建民. 支气管扩张症生活质量问卷中文版的临床应用评价[J]. 现代医学，2021，49(4):441-444.
[43]	SPINOU A, SIEGERT R J, GUAN W J，et al. The development and validation of the Bronchiectasis Health Questionnaire[J]. Eur Respir J，2017，49(5):1601532. DOI：10.1183/13993003.01532-2016.
[44]	GISSEL T N, HVASS M, FLY J，et al. Translation and linguistic validation of the Bronchiectasis Health Questionnaire（BHQ）into Danish[J]. Dan Med J，2020，67(3):A09190520.
[45]	JONES P W, HARDING G, BERRY P，et al. Development and first validation of the COPD Assessment Test[J]. Eur Respir J，2009，34(3):648-654. DOI：10.1183/09031936.00102509.
[46]	AMALAKUHAN B, MASELLI D J, MARTINEZ-GARCIA M A. Update in bronchiectasis 2014[J]. Am J Respir Crit Care Med，2015，192(10):1155-1161. DOI：10.1164/rccm.201505-0926UP.
[47]	JONES P W, BRUSSELLE G, DAL NEGRO R W，et al. Properties of the COPD assessment test in a cross-sectional European study[J]. Eur Respir J，2011，38(1):29-35. DOI：10.1183/09031936.00177210.
[48]	GIL H I, ZO S, JONES P W，et al. Clinical characteristics of COPD patients according to COPD assessment test（CAT）score level：cross-sectional study[J]. Int J Chron Obstruct Pulmon Dis，2021，16:1509-1517. DOI：10.2147/COPD.S297089.
[49]	FINCH S, LASKA I F, ABO-LEYAH H，et al. Validation of the COPD assessment test（CAT）as an outcome measure in bronchiectasis[J]. Chest，2020，157(4):815-823. DOI：10.1016/j.chest.2019.10.030.
[50]	TSILIGIANNI I G, VAN DER MOLEN T, MORAITAKI D，et al. Assessing health status in COPD. A head-to-head comparison between the COPD assessment test（CAT）and the clinical COPD questionnaire（CCQ）[J]. BMC Pulm Med，2012，12:20. DOI：10.1186/1471-2466-12-20.
[51]	VAN DER MOLEN T, WILLEMSE B W, SCHOKKER S，et al. Development，validity and responsiveness of the clinical COPD questionnaire[J]. Health Qual Life Outcomes，2003，1:13. DOI：10.1186/1477-7525-1-13.
[52]	ALMA H, DE JONG C, JELUSIC D，et al. Baseline health status and setting impacted minimal clinically important differences in COPD：an exploratory study[J]. J Clin Epidemiol，2019，116:49-61. DOI：10.1016/j.jclinepi.2019.07.015.
[53]	BIRRING S S, PRUDON B, CARR A J，et al. Development of a symptom specific health status measure for patients with chronic cough：Leicester Cough Questionnaire（LCQ）[J]. Thorax，2003，58(4):339-343. DOI：10.1136/thorax.58.4.339.
[54]	MURRAY M P, TURNBULL K, MACQUARRIE S，et al. Validation of the Leicester cough questionnaire in non-cystic fibrosis bronchiectasis[J]. Eur Respir J，2009，34(1):125-131. DOI：10.1183/09031936.00160508.
[55]	林嵘嘉，车国卫，徐志华，等. 肺癌患者电视胸腔镜手术后咳嗽的影响因素分析：单中心前瞻性研究[J]. 中国胸心血管外科临床杂志，2017，24(10):748-752.
[56]	HAUKELAND-PARKER S, HASVIK E, JELSNESS-JØRGENSEN L P，et al. Cross-cultural adaptation and validation of the Norwegian version of the Leicester Cough Questionnaire in chronic obstructive pulmonary disease[J]. Physiother Theory Pract，2021:1-10. DOI：10.1080/09593985.2021.1911012.
[57]	BROKKAAR L, UIL S M, VAN DEN BERG J W K. Minimal clinically important difference（MCID）of the Dutch version of the Leicester cough questionnaire and baseline predictors of reaching the mcid after six months[J]. Chest，2007，132(4):468B. DOI：10.1378/chest.132.4_MeetingAbstracts.468b.
[58]	PORNSURIYASAK P, THUNGTITIGUL P, KAWAMATAWONG T，et al. Minimal clinically important differences （MCIDs） of the Thai version of the Leicester cough questionnaire for subacute and chronic cough[J]. Value Health Reg Issues，2017，12:57-62. DOI：10.1016/j.vhri.2017.03.009.
[59]	BIRRING S, MUCCINO D, BACCI E D，et al. Defining minimal clinically important differences（MCID）on the Leicester cough questionnaire（LCQ）：analyses of a phase 2 randomized controlled trial in chronic cough[J]. J Allergy Clin Immunol，2019，143(2):AB52. DOI：10.1016/j.jaci.2018.12.158.
[60]	LAUNOIS C, BARBE C, BERTIN E，et al. The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity：a pilot study[J]. BMC Pulm Med，2012，12:61. DOI：10.1186/1471-2466-12-61.
[61]	郭伟洪，袁小玲，吕燕华，等. 噻托溴铵粉吸入剂治疗支气管扩张并呼吸衰竭的疗效观察[J]. 临床肺科杂志，2017，22(8):1372-1374,1379. DOI：10.3969/j.issn.1009-6663.2017.08.004.
[62]	焦瑞，刘双. 支气管扩张症急性加重的危险因素及意义[J]. 中华医学杂志，2015，95(4):273-276. DOI：10.3760/cma.j.issn.0376-2491.2015.04.008.
[63]	赵明，王玉彩. 支气管扩张患者营养风险与疾病严重程度相关性研究[J]. 实用临床医药杂志，2019，23(3):60-62,66. DOI：10.7619/jcmp.201903016.
[64]	FRENCH C T, IRWIN R S, FLETCHER K E，et al. Evaluation of a cough-specific quality-of-life questionnaire[J]. Chest，2002，121(4):1123-1131. DOI：10.1378/chest.121.4.1123.
[65]	POLLEY L, YAMAN N, HEANEY L，et al. Impact of cough across different chronic respiratory diseases：comparison of two cough-specific health-related quality of life questionnaires[J]. Chest，2008，134(2):295-302. DOI：10.1378/chest.07-0141.
[66]	LECHTZIN N, HILLIARD M E, HORTON M R. Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis[J]. Chest，2013，143(6):1745-1749. DOI：10.1378/chest.12-2870.
[67]	CRAWFORD B, MONZ B, HOHLFELD J，et al. Development and validation of a cough and sputum assessment questionnaire[J]. Respir Med，2008，102(11):1545-1555. DOI：10.1016/j.rmed.2008.06.009.
[68]	TAGAYA E, YAGI O, SATO A，et al. Effect of tiotropium on mucus hypersecretion and airway clearance in patients with COPD[J]. Pulm Pharmacol Ther，2016，39:81-84. DOI：10.1016/j.pupt.2016.06.008.
[69]	李雪，祝勇，郭亚丽，等. 升阳益胃汤加减治疗支气管扩张症稳定期脾肺气虚、痰热蕴肺证临床疗效研究[J]. 辽宁中医杂志，2021，48(6):118-121. DOI：10.13192/j.issn.1000-1719.2021.06.033.
[70]	ALTENBURG J, WORTEL K, DE GRAAFF C S，et al. Validation of a visual analogue score（LRTI-VAS）in non-CF bronchiectasis[J]. Clin Respir J，2016，10(2):168-175. DOI：10.1111/crj.12198.
[71]	卢刚，陈宇清，丁凤鸣，等. 不同维持剂量阿奇霉素长程治疗对稳定期支气管扩张症患者肺功能和生命质量的影响[J]. 中国医师进修杂志，2018，41(6):493-497. DOI：10.3760/cma.j.issn.1673-4904.2018.06.004.

量表名称		维度	条目数	积分解读	MCID估值
普适性量表
	SF-36	生理功能、生理职能、躯体疼痛、总体健康、生命活力、社交功能、情感职能、心理健康	36	分值越高，生存质量越差	SWIGRIS^[15]：3分（分布法）；2~4分（锚定法）
	HADS	焦虑、抑郁	14	分值越高，焦虑抑郁情绪越严重	SMID^[17]：1.3~1.8分（HADS-A：锚定法+分布法）；1.5~1.7分（HADS-D：锚定法+分布法） WYNNE^[18]：2分（锚定法+分布法）
疾病特异性量表
	SGRQ	症状、活动、日常生活影响	50	0~100分，分值越高，生存质量越差	JONES^[26]：4分（锚定法） SWIGRIS^[27]：7分REHMAN^[28]：5.07分（锚定法） 6.05分（分布法）
	CRQ	呼吸困难、疲劳、心理功能、对疾病的控制	41	41~287分，分值越高，生存质量越好	JAESCHKE^[4]：呼吸领域为3分（锚定法） WYRWICH^[32]：0.5分/条目（专家意见法+分布法）
	SOLDQ	身体功能、情绪功能、应对技巧、治疗满意度	29	0~400分，分值越高，生存质量越好	—
	QOL-B	生理功能、角色功能、活力、情绪功能、社会功能、治疗负担、健康感觉、呼吸症状	37	0~100分，分值越高，生活质量越好	QUITTNER^[39]：7~10分（锚定法+分布法） OLVEIRA^[40]：呼吸领域为6.8分（分布法） QUELLHORST^[41]：8.5~14.1（分布法）
	BHQ	呼吸道症状、身体功能、心理健康、药物和治疗、社会功能	10	分值越高，生存质量越好	—
	CAT	咳嗽、咳痰、胸闷、睡眠、精力、情绪、运动耐力、日常运动影响	8	0~40分，分值越高，生存质量越差	SMID^[17]：2~3分（锚定法+分布法） FINCH^[49]：4分（锚定法+分布法） TSILIGIANNI^[50]：3.76分（分布法）
	CCQ	症状、功能、精神状态	10	0~6分，分值越高，生存质量越差	TSILIGIANNI^[50]：0.41分（分布法）
症状特异性量表
	LCQ	生理、心理、社交	19	3~21分，分值越高，咳嗽对生存质量影响越小	BROKKAAR^[57]：3分BIRRING^[59]：1.5~2.0分
	mMRC	呼吸困难	4	0~4分，分值越高，呼吸困难越严重	—
	CQLQ	身体不适、社会心理问题、职业技能、情感健康、极端身体不适、人身安全恐惧	28	28~112分，分值越高，生活质量越差	LECHTZIN^[66]：5.0~5.7（分布法）
	CASA-Q	咳嗽症状，咳嗽影响，咳痰症状、痰液影响	20	分值越高，生存质量越差	—
	LRTI-VAS	呼吸困难、疲劳、咳嗽、疼痛程度、痰色	5	5~50分，分值越高，症状越严重	—

量表名称		维度	条目数	积分解读	MCID估值
普适性量表
	SF-36	生理功能、生理职能、躯体疼痛、总体健康、生命活力、社交功能、情感职能、心理健康	36	分值越高，生存质量越差	SWIGRIS^[15]：3分（分布法）；2~4分（锚定法）
	HADS	焦虑、抑郁	14	分值越高，焦虑抑郁情绪越严重	SMID^[17]：1.3~1.8分（HADS-A：锚定法+分布法）；1.5~1.7分（HADS-D：锚定法+分布法） WYNNE^[18]：2分（锚定法+分布法）
疾病特异性量表
	SGRQ	症状、活动、日常生活影响	50	0~100分，分值越高，生存质量越差	JONES^[26]：4分（锚定法） SWIGRIS^[27]：7分REHMAN^[28]：5.07分（锚定法） 6.05分（分布法）
	CRQ	呼吸困难、疲劳、心理功能、对疾病的控制	41	41~287分，分值越高，生存质量越好	JAESCHKE^[4]：呼吸领域为3分（锚定法） WYRWICH^[32]：0.5分/条目（专家意见法+分布法）
	SOLDQ	身体功能、情绪功能、应对技巧、治疗满意度	29	0~400分，分值越高，生存质量越好	—
	QOL-B	生理功能、角色功能、活力、情绪功能、社会功能、治疗负担、健康感觉、呼吸症状	37	0~100分，分值越高，生活质量越好	QUITTNER^[39]：7~10分（锚定法+分布法） OLVEIRA^[40]：呼吸领域为6.8分（分布法） QUELLHORST^[41]：8.5~14.1（分布法）
	BHQ	呼吸道症状、身体功能、心理健康、药物和治疗、社会功能	10	分值越高，生存质量越好	—
	CAT	咳嗽、咳痰、胸闷、睡眠、精力、情绪、运动耐力、日常运动影响	8	0~40分，分值越高，生存质量越差	SMID^[17]：2~3分（锚定法+分布法） FINCH^[49]：4分（锚定法+分布法） TSILIGIANNI^[50]：3.76分（分布法）
	CCQ	症状、功能、精神状态	10	0~6分，分值越高，生存质量越差	TSILIGIANNI^[50]：0.41分（分布法）
症状特异性量表
	LCQ	生理、心理、社交	19	3~21分，分值越高，咳嗽对生存质量影响越小	BROKKAAR^[57]：3分BIRRING^[59]：1.5~2.0分
	mMRC	呼吸困难	4	0~4分，分值越高，呼吸困难越严重	—
	CQLQ	身体不适、社会心理问题、职业技能、情感健康、极端身体不适、人身安全恐惧	28	28~112分，分值越高，生活质量越差	LECHTZIN^[66]：5.0~5.7（分布法）
	CASA-Q	咳嗽症状，咳嗽影响，咳痰症状、痰液影响	20	分值越高，生存质量越差	—
	LRTI-VAS	呼吸困难、疲劳、咳嗽、疼痛程度、痰色	5	5~50分，分值越高，症状越严重	—

Application of Minimal Clinically Important Difference in Outcome Assessment Tools for Bronchiectasis Treatment

最小临床重要差值在支气管扩张症疗效测评工具中的应用与思考

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 71

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	HAN Xiao, LI Qiyu, GE Pu, FAN Siyuan, LIU Diyue, WU Yibo, ZHANG Qingshuang. The Impact of Behavioral Lifestyle on Quality of Life in Hypertensive Patients [J]. Chinese General Practice, 2025, 28(26): 3248-3258.
[2]	WU Yue, WANG Xuetong, KE Bilian. Evaluation of Vision-related Quality of Life in Myopic Macular Degeneration Patients with Low Vision and Associated Factors [J]. Chinese General Practice, 2025, 28(23): 2908-2914.
[3]	WEN Min, ZHOU Yongling, LIU Jingjing, JIANG Keqing, LIU Juan, ZHU Xiaodan. The Effect and Mechanism of Compensatory Cognitive Training Based on mHealth APP on Stable Schizophrenia Patients [J]. Chinese General Practice, 2025, 28(22): 2819-2825.
[4]	FAN Jianing, CHEN Jieting, WANG Ziqi, FAN Jinhe, JING Mingxia. Analysis of the Development Trajectory of Health-related Quality of Life in Middle-aged and Elderly Patients with Cardiometabolic Diseases and the Influencing Factors [J]. Chinese General Practice, 2025, 28(08): 923-932.
[5]	YAO Dingye, LUO Guiping, SUN Junsheng, REN Jingjing. Diagnosis and Treatment of Halitosis: a General Practice Perspective [J]. Chinese General Practice, 2025, 28(07): 900-904.
[6]	WU Jun, ZHANG Ling, GU Dongwei, ZHENG Lei, ZHAO Zhuxiang, ZHAO Ziwen. Comparative Study of Pathogenic Bacteria in Patients of Bronchiectasis with and without Chronic Obstructive Pulmonary Disease [J]. Chinese General Practice, 2025, 28(06): 729-736.
[7]	LI Hongmei, ZHANG Yimin, WANG Yong, ZHANG Yurong, JIA Xiao, YU Jingjing, SANG Die. Aerobic Exercise Improves Physique and Quality of Life in Breast Cancer Patients During Anthracycline-based Chemotherapy: a Randomized Controlled Trial [J]. Chinese General Practice, 2025, 28(03): 285-292.
[8]	NIU Guohui, XIE Jiayang, ZHU Dengna, CUI Bo, ZHAO Huiling, WANG Mingmei, FENG Huanhuan, ZHANG Mengmeng, LI Tingting. Clinical Effect of Vitamin D on Children with Global Developmental Delay [J]. Chinese General Practice, 2025, 28(03): 346-351.
[9]	QI Mingrui, WANG Wenjuan, TIAN Limin. Health-related Quality of Life of Elderly Hypertensive Population in Northwest China [J]. Chinese General Practice, 2025, 28(02): 199-207.
[10]	FENG Caixia, WANG Zengshuai, MU Hailin, YANG Hanxuan, TAMIR. Effect of Parkinson's Disease Management Model Dominated by Movement Disorder Specialists and Centered on Community Doctors [J]. Chinese General Practice, 2024, 27(34): 4280-4285.
[11]	LI Chunyang, WANG Jiajia, WEI Mengyu, LI Jiansheng. Research Status of Patient-reported Outcome Measurements for Acute Exacerbation of Chronic Obstructive Pulmonary Disease [J]. Chinese General Practice, 2024, 27(31): 3896-3904.
[12]	HAN Shuai, ZHU Xuejiao, SHU Jie, CHEN Guoling. Development and Validation of a Cloud Follow-up Service Experience Scale for Patients with Chronic Diseases [J]. Chinese General Practice, 2024, 27(28): 3552-3559.
[13]	ZHAO Ting, ZHANG Yan, WU Lanxin, MENG Lixue, LIU Li. A Qualitative Study of Community-dwelling Elderly People' Experience of Multimorbidity [J]. Chinese General Practice, 2024, 27(25): 3143-3149.
[14]	RAN Zhuorui, SUN Ruixin, JIA Jingyi, CHE Zhaoyu, LI Ruixi, HE Yaping, CHU Qiao. Advances in Life Goal Adjustment Ability of Cancer Patients and Its Effect on Physical and Mental Health [J]. Chinese General Practice, 2024, 27(23): 2822-2828.
[15]	YU Haiyan, WANG Haitang, DU Zhaohui. Effects of Intervention Based on Behavioral Change Wheel and Behavioral Change Technologys on the Behavior, Ambulatory Blood Pressure and Quality of Life in Patients with Hypertension [J]. Chinese General Practice, 2024, 27(22): 2714-2723.